Company intelligence / Profile preview

Xueyinghua

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Xueyinghua Pharmaceutical is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative protein degradation therapies. The company leverages its proprietary PROTAC (Proteolysis Targeting Chimera) platform to design small molecules that selectively degrade disease-causing proteins. Its lead candidate, XYH-001, is a potent BTK degrader currently being evaluated for the treatment of B-cell malignancies and potentially autoimmune disorders. Xueyinghua aims to address unmet medical needs in oncology and immunology by overcoming resistance mechanisms associated with traditional inhibitors.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeProteolysis-targeting chimera therapy
Industry: Biotech

Beyond the preview

Go deeper on Xueyinghua.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xueyinghua.

Explore the full profile